Viome Life Sciences is a technology company.
Viome Life Sciences has raised $10.0M across 1 funding round.
Viome Life Sciences has raised $10.0M in total across 1 funding round.
Viome Life Sciences has raised $10.0M in total across 1 funding round.
Viome Life Sciences's investors include Baird Capital, Endeavor Venture Funds, Presight Capital, What If Ventures, Tim Kendall.
Viome Life Sciences is a biotechnology company founded in 2016 that develops AI-powered diagnostic tests analyzing microbiome, transcriptome, and metabolome data to deliver personalized nutrition, supplement, and lifestyle recommendations.[1][2][3] It serves consumers seeking to prevent and reverse chronic diseases, cancer, and aging by addressing root causes through systems biology, with products like at-home health tests and health scores derived from over 600,000 samples.[2][5][6] The company has demonstrated strong growth momentum, raising $175 million total funding including an $86.5 million Series C (with $67 million announced in 2022 led by Bold Capital Group), expanding collaborations like with GSK for cancer and autoimmune therapies, and scaling operations across offices in Bellevue, Bothell, and New York.[1][2][6]
Viome Life Sciences emerged in 2016 from the vision of its founding CSO, Momo Vuyisich, PhD, an entrepreneur-scientist with over 25 years in biology, chemistry, and bioinformatics, who led programs from ideation to commercial products.[1][2][4] The idea stemmed from recognizing that over 90% of diseases link not to human DNA but to microbial gene expression and biochemicals, prompting a shift from descriptive microbiome studies to actionable metatranscriptomics and machine learning for personalized health interventions.[2][5] Early traction built on analyzing 300,000+ specimens for chronic conditions, evolving into consumer diagnostics via Viome Consumer Sciences and partnerships with investors like Khosla Ventures, which fueled pivotal expansions in precision testing.[2][4][6]
Viome rides the microbiome revolution in precision medicine, leveraging AI to shift healthcare from reactive treatment to proactive prevention amid rising chronic disease epidemics.[2][5] Timing aligns with maturing metatranscriptomics tech and big data from consumer samples, outpacing DNA-only competitors by revealing functional microbial dynamics that influence 90%+ of non-genetic diseases.[1][2] Market forces like aging populations, post-pandemic health awareness, and pharma interest (e.g., GSK deal) favor its model, while it influences the ecosystem through data-sharing grants, longevity research, and consumer-to-clinical pipelines that democratize molecular insights.[2][4][5]
Viome is poised to lead AI-driven longevity and precision diagnostics, with next steps including GSK-expanded cancer/autoimmune therapies, more predictive models from growing sample libraries, and global scaling of at-home tests.[2][6] Trends like multi-omics integration and regulatory nods for microbiome interventions will accelerate its path, potentially evolving influence from consumer wellness to transformative pharma partnerships and population health tools. This positions Viome to truly make illness optional, fulfilling its founding mission in a data-rich biotech era.[1][2]
Viome Life Sciences has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series C in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $10.0M Series C | Baird Capital, Endeavor Venture Funds, Presight Capital, What If Ventures, Tim Kendall |